Theravance Biopharma (TBPH) EBT (2013 - 2026)
Theravance Biopharma (TBPH) reported EBT of -$6.5 million for Q1 2026, up 54.24% year-over-year from -$4.2 million in Q1 2025, and up 81.68% quarter-over-quarter from -$35.3 million in Q4 2025.
Theravance Biopharma (TBPH) EBT (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of EBT data on file, last reported at -$6.5 million in Q1 2026.
- EBT for Q1 2026 came in at -$6.5 million, up 54.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.5 million (up 1756.5% YoY), and the FY2025 annual result was $20.9 million, up 935.6% from the prior year.
- EBT improved to -$6.5 million in Q1 2026 per TBPH's latest filing, from -$35.3 million in the prior quarter.
- Over five years, EBT peaked at $73.2 million in Q2 2025 and troughed at -$39.7 million in Q1 2022.
- A 5-year average of -$7.4 million and a median of -$14.1 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT soared 851.38% in 2024, then sank 193.72% in 2025.
- A 5-year view of EBT shows it stood at -$14.3 million in 2022, then jumped by 64.82% to -$5.0 million in 2023, then soared by 851.38% to $37.7 million in 2024, then plunged by 193.72% to -$35.3 million in 2025, then surged by 81.68% to -$6.5 million in 2026.
- Business Quant data shows TBPH's EBT at -$6.5 million in Q1 2026, -$35.3 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -6.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.47 Mn |
| Dec 31, 2025 | -35.32 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | 73.21 Mn |
| Mar 31, 2025 | -14.14 Mn |
| Dec 31, 2024 | 37.69 Mn |
| Sep 30, 2024 | -10.05 Mn |
| Jun 30, 2024 | -15.22 Mn |
| Mar 31, 2024 | -10.40 Mn |
| Dec 31, 2023 | -5.02 Mn |
| Sep 30, 2023 | -7.58 Mn |
| Jun 30, 2023 | -14.19 Mn |
| Mar 31, 2023 | -22.48 Mn |
| Dec 31, 2022 | -14.26 Mn |
| Sep 30, 2022 | -16.02 Mn |
| Jun 30, 2022 | -22.80 Mn |
| Mar 31, 2022 | -39.74 Mn |
| Dec 31, 2021 | -57.97 Mn |
| Sep 30, 2021 | -55.92 Mn |
| Jun 30, 2021 | -52.63 Mn |